Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid

Botulism Clinical Trial

Official title:
Phase 2b, Two-part, Open-label, Uncontrolled Study to Evaluate Safety, Tolerability, and Immunogenicity of a Single 40-µg Dose of Recombinant Botulinum Vaccine A/B (rBV A/B) for the Production of BabyBIG® in Volunteers Previously Immunized With Pentavalent Botulinum Toxoid for Occupational Protection

Status Completed

Clinical Trial Summary

Study rBV A/B-CL-001 is a Phase 2b, 2-part, open-label, uncontrolled study to evaluate safety, tolerability, and immunogenicity of a single dose of recombinant botulinum vaccine A/B (rBV A/B) for the production of BabyBIG in volunteers previously immunized with the pentavalent botulinum (PBT) toxoid. This study is designed to determine neutralizing antibody levels for botulinum toxin types A and B in healthy subjects who were previously immunized with the PBT for occupational protection and who receive the rBV A/B. Subjects with titers of the neutralizing antibodies against the toxins would be candidates for plasma donation for BabyBIG production.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

Botulism

Clinical Trial Details

NCT number	NCT01701999
Study type	Interventional
Source	California Department of Public Health
Contact
Status	Completed
Phase	Phase 2
Start date	February 2013
Completion date	October 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03603665` - A Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults	Phase 1
Not yet recruiting	`NCT04550793` - Using Shear Wave Ultrasound Elastography for Follow up After Anti-spastic Intervention Among Stroke Patients
Completed	`NCT01441557` - Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism	Phase 2/Phase 3
Recruiting	`NCT05769478` - Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA	Phase 1
Withdrawn	`NCT01940315` - Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B	Phase 3
Enrolling by invitation	`NCT02051062` - BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients	Phase 4
Completed	`NCT02055183` - BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin
Completed	`NCT01357213` - Phase 1 PK Study of XOMA 3AB	Phase 1
Completed	`NCT03676634` - Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG®	Phase 2
Completed	`NCT00314080` - Treatment of Survivors After Botulism Outbreak	N/A
Not yet recruiting	`NCT06112834` - Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG®	Phase 2
Completed	`NCT00348426` - Botulism Outbreak in Thailand (Episode II)	Phase 4
Completed	`NCT00004401` - Study of Human Botulism Immunoglobulin in Infants With Botulism	N/A
Completed	`NCT02779140` - Phase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632	Phase 1